ArticleInternational journal of molecular sciences2026
Skewed MHC Class I Peptide Presentation in Psoriatic Arthritis.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Given the strong association between major histocompatibility complex (MHC) class I and psoriatic arthritis (PsA), and the role of the MHC in antigen presentation potentially driving immunopathology, we performed mass spectrometry-based immunopeptidome analysis to identify MHC class I-bound peptides in PsA. MHC class I expression on circulating immune cells was determined by flow cytometric analysis. MHC class I-bound peptides were isolated via immunoaffinity purification and identified by mass spectrometry in PsA patients and healthy controls. MHC class I expression was increased on circulating immune cells in PsA. MHC class I immunopeptidome analysis revealed a high prevalence of peptides of nine-amino-acid length originating from intracellular source proteins, typical for MHC class I antigen presentation. Analysis of the MHC class I immunopeptidome showed a greater relative abundance of glutamic acid at position 2 in nonamers from PsA patients, but not controls. This finding was further corroborated by an unsupervised clustering analysis showing five different clusters in healthy individuals and six in PsA, with one featuring higher abundance of glutamic acid at position 2. The glutamic acid-containing PEQLRKLFI peptide from the heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) was exclusively identified in PsA patients both via MHC class I immunopeptidome analysis and via PEPperMap epitope mapping. In PsA, MHC class I expression is increased on circulating immune cells, and the MHC class I immunopeptidome is perturbed, with disease-related skewing towards greater relative abundance of glutamic acid at position 2 in nonamers and presentation of a unique peptide motif from the putative autoantigen hnRNP A1.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.